Ranbaxy Laboratories Limited

[savio13]

Ranbaxy Laboratories Limited, India's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company, producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranked 8th amongst the global generic pharmaceutical companies, Ranbaxy today has a presence in 23 of the top 25 pharmaceutical markets of the world. The Company has a global footprint in 49 countries, world-class manufacturing facilities in 11 countries and serves customers in over
125 countries.

In June 2008, Ranbaxy entered into an alliance with one of the largest Japanese innovator companies, Daiichi Sankyo Company Ltd., to create an innovator and generic pharmaceutical powerhouse. The combined entity now ranks among the top 15 pharmaceutical companies, globally. The transformational deal will place Ranbaxy in a higher growth trajectory and it will emerge stronger in terms of its global reach and in its capabilities in drug development and manufacturing.

Ranbaxy Laboratories Limited, India : Pharmaceuticals Business, pharmaceutical company india, pharma outsourcing india, pharmaceuticals brand, pharmaceuticals intellectual property

[marquais_v]

Products

Using the finest R&D and Manufacturing facilities, Ranbaxy Laboratories Limited manufacture and markets generic pharmaceuticals, value added generic pharmaceuticals, branded generics, active Pharmaceuticals (API) and intermediates.

The Company remains focused on ascending the value chain in the marketing of pharmaceutical substances and is determined to bring in increased revenues from dosage forms sales.

Ranbaxy's diverse product basket of over 5,000 SKUs available in over 125 countries worldwide, encompasses a wide therapeutic mix covering a majority of the chronic and acute segments. Healthcare trends project that the chronic treatment segments will outpace the acute treatment segments, primarily driven by a growing aging population and dominance of lifestyle diseases. Our robust performance in Cardiovasculars, Central Nervous System, Respiratory, Dermatology, Orthopedics, Nutritionals and Urology segments, clearly indicates that the Company has strengthened its presence in the fast-growing chronic and lifestyle disease segments. Ranbaxy's top 20 products, ranging from Anti-infectives to Dermatologicals, account for revenues of over US $ 600 Mn.
Top Ten Molecules


Simvastatin


Amoxy+Clav Potas Com


Amoxycillin


Ciprofloxacin


Isotretinon


Cephalexin


Ketorolac Tromethamine


Cefaclor


Clarithromycin


Cefuroxime Axetil

[anujchhabra07]

Business Development & Partnerships

Ranbaxy Laboratories Limited, India's largest pharmaceutical company, headquartered in India, is an integrated, research based, international pharmaceutical company, producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. It is ranked amongst the top ten generic companies worldwide. The Company has manufacturing operations in 11 countries with a ground presence in 49 countries and its products are available in over 125 countries. The Company is driven by its ambition to achieve US $5 Bn Sales by 2012 and be amongst the top five generic players worldwide. To translate these objectives into reality and to optimize value creation, the Company has adopted a multi-pronged strategy. Acquisition of generic brands overseas, strong emphasis on brand marketing in the US and Europe, entering high potential new markets with value added product offerings, are the major thrust areas. Successful business development transactions form a key component of it's business strategy.

In each of our partnerships, we strive to build enduring, mutually beneficial relationships that can produce positive results for both parties.

We are interested in sales and marketing partnerships and product acquisition opportunities in all the markets where we operate. We are exploring opportunities through Licensing and Alliances to draw maximum value from such arrangements. We continue to evaluate opportunities to add to our product basket, enhance our therapeutic presence and expand our distribution reach.

We are also interested in building winning drug discovery and development collaborations in the following therapeutic areas:

Anti-infectives
Inflammation & Respiratory
Metabolic Diseases
Oncology

In addition, we have active R&D programs in oral controlled release drug delivery systems and are looking for suitable partnerships. We are also actively evaluating options for acquiring new technology platforms to develop differentiated high margin products.

For business development, licensing, and partnership enquiries please contact:


Dr. Shyam Bishen, Ph.D., MBA
Vice President, Corporate Development

Ranbaxy Pharmaceuticals Inc.
600 College Road East
Princeton, NJ 08540, USA
Phone: 001 (609) 720-5377
E-mail: